MinettaCLiuMD

Oncology • Rochester, MN

Mayo Clinic

Join to view full profile

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liu's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1995

Certifications & Licensure

MN State Medical License 2013 - 2024
DC State Medical License 1997 - 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer Start of enrollment: 2001 Apr 01
Terminated
Phase 2
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer Start of enrollment: 2000 Oct 01
Completed
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
Suspended
Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice Start of enrollment: 2019 Dec 12
Completed
Not Applicable
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Start of enrollment: 2020 Sep 23
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.
Eric Michael Lander, Vasily N Aushev, Brandon M Huffman, Diana Hanna, Punashi Dutta
JCO Precision Oncology. 2024-12-01
2 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Corre...
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley
Journal of Clinical Oncology. 2024-11-01
2 citations
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors.
Ekaterina Kalashnikova, Vasily N Aushev, Allyson Koyen Malashevich, Antony Tin, Shifra Krinshpun
Molecular Oncology. 2024-11-01

Abstracts/Posters

Molecular Alterations in Adult Histiocytic Neoplasms
Minetta C Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.
2019 ASCO Annual Meeting - 6/1/2019
Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Applications of Liquid Biopsies in Metastatic Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

First of Its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall SurvivalSeptember 14th, 2024
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall SurvivalSeptember 8th, 2024
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual MeetingApril 14th, 2023
Join now to see all

Committees

Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present